文献速递头颈外科

头颈癌放疗或放化疗后长期阿片类药物使用

Long-Term Opioid Use Following Radiation or Chemoradiation for Head and Neck Cancer.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2026-10-01

这项单中心队列研究纳入789例接受根治性放疗或放化疗的非转移性头颈癌患者,评估治疗结束后3个月和6个月阿片类药物使用情况。结果显示,放疗后3个月和6个月分别有70.0%和47.3%的患者继续使用处方阿片类药物;既往阿片使用、曾吸烟和转诊姑息治疗与3个月时阿片使用相关。

要点

  • 放疗后3个月和6个月继续使用阿片类药物的比例分别为70.0%和47.3%。
  • 既往阿片使用、曾吸烟和姑息治疗转诊与3个月时阿片使用独立相关。
  • 在放疗前未使用阿片类的患者中,3个月和6个月继续使用的比例分别为57.8%和37.8%。

核心结论

  • 头颈癌患者放疗或放化疗后3个月和6个月继续使用阿片类药物的比例较高,分别为70.0%和47.3%。
  • 既往阿片使用、曾吸烟和姑息治疗转诊与3个月时阿片使用相关,提示需针对镇痛与长期依赖风险开展阿片药物管理项目。

研究设计与样本

  • 单中心队列研究,纳入2011年10月至2023年12月在俄亥俄州立大学综合癌症中心诊断的非转移性头颈癌患者789例,均接受根治性放疗或放化疗。
  • 中位年龄61岁(IQR 55-68岁),男性639例(81.0%),中位随访46.7个月(IQR 31.1-56.1个月)。

主要发现

  • 从诊断至放疗后6个月,750例(95.1%)患者接受过处方阿片类药物。
  • 放疗后3个月和6个月继续使用处方阿片类药物的患者分别为552例(70.0%)和373例(47.3%)。
  • 3个月时阿片使用相关因素包括曾吸烟(AOR 1.55;95%CI 1.04-2.31)、姑息治疗转诊(AOR 3.90;95%CI 2.57-6.09)和放疗前阿片使用(AOR 2.57;95%CI 1.82-3.63)。
  • 在296例(37.5%)放疗前未使用阿片类的患者中,体重不足(AHR 7.36;95%CI 3.40-15.90)和姑息治疗转诊(AHR 1.42;95%CI 1.10-1.83)与首次阿片使用时间缩短相关。
  • 放疗前未使用阿片类的患者中,171例(57.8%)和112例(37.8%)在放疗后3个月和6个月继续使用阿片类药物。

临床怎么用

  • 对头颈癌放疗或放化疗患者,应关注治疗结束后3个月和6个月的阿片类药物持续使用情况。
  • 对曾吸烟、放疗前已使用阿片或转诊姑息治疗的患者,可考虑针对性阿片药物管理以平衡镇痛与依赖风险。

局限性

  • 本研究为单中心队列研究,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with head and neck cancer represent a vulnerable patient population for potential chronic opioid use. Prior institutional studies on chronic opioid use had limited sample sizes, and the incidence of and risk factors for chronic opioid use need further investigation. OBJECTIVE: To evaluate the proportion of patients with opioid use and factors associated with opioid use 3 months following chemoradiation or radiation treatment for head and neck cancer. DESIGN, SETTING, AND PARTICIPANTS: This single-institution cohort study at The Ohio State Comprehensive Cancer Center included patients diagnosed with nonmetastatic head and neck cancer between October 2011 and December 2023 who received definitive radiation or chemoradiation. EXPOSURE: Receipt of definitive radiation or chemoradiation. MAIN OUTCOMES AND MEASURES: The primary end point was opioid use 3 months after completing radiation in the entire cohort. Logistic multivariable analysis was performed to evaluate variables associated with opioid use at this time point. Secondary end points were opioid use at 6 months and time to first opioid use in an opioid-naive patient subgroup. RESULTS: A total of 789 patients met the study's inclusion criteria (639 men [81.0%]; median age, 61 years [IQR, 55-68 years]). Median follow-up was 46.7 months (IQR, 31.1-56.1 months). Between diagnosis and 6 months following radiation, 750 patients (95.1%) received prescription opioids. At 3 and 6 months following radiation, 552 (70.0%) and 373 (47.3%) patients, respectively, continued taking prescription opioids. Patients were more likely to be taking opioids at 3 months following radiation if they were former smokers (adjusted odds ratio [AOR], 1.55; 95% CI, 1.04-2.31), were referred to palliative care (AOR, 3.90; 95% CI, 2.57-6.09), or had taken opioids prior to radiation (AOR, 2.57; 95% CI, 1.82-3.63). Among 296 patients who were opioid-naive prior to radiation (37.5%), time to first opioid use was shorter for those with underweight status (adjusted hazard ratio [AHR], 7.36; 95% CI, 3.40-15.90) and those referred to palliative care (AHR, 1.42; 95% CI, 1.10-1.83). Of the opioid-naive patients, 171 (57.8%) and 112 (37.8%) continued taking opioids at 3 and 6 months following radiation, respectively. CONCLUSIONS AND RELEVANCE: In this cohort study, 70.0% and 47.3% of patients with head and neck cancer continued taking opioids at 3 and 6 months following treatment, respectively. Factors associated with opioid use at 3 months included prior opioid use, former smoking status, and palliative care referral. These findings suggest that targeted opioid stewardship programs that consider both analgesia and long-term dependency risk are merited.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Desai O, Kotler A, Virk J, et al. Long-Term Opioid Use Following Radiation or Chemoradiation for Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42821288. doi:10.1001/jamaoto.2026.2536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。